A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention.

Trial Profile

A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Tirofiban (Primary)
  • Indications Coronary artery disease; Thrombosis
  • Focus Therapeutic Use
  • Acronyms ATLAST-PCI
  • Sponsors Medicure
  • Most Recent Events

    • 09 Mar 2018 Status changed from suspended to withdrawn prior to enrolment.
    • 18 Jan 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 26 Sep 2011 Planned initiation date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top